ArticleScientific reports2025
A prevalence study focusing on hospitalized COPD related pulmonary hypertension.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review.International journal of chronic obstructive pulmonary disease · 2026Review
- Development and internal validation of a machine learning-based prediction model for pulmonary hypertension in COPD.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) contributes to mortality. Existing epidemiological research is limited in scale, leading to varied prevalence estimates. Hereby, we aim to evaluate the prevalence and impact of COPD-related PH in individuals with COPD. We used medical-claims data from the national health insurance database (NHIRD) of Taiwan (2009 to 2018). The index date was defined as the initial hospitalization for COPD. We identified patients above 40 year-old with a COPD diagnosis from inpatient claims data and stratified rates of COPD-related PH by gender, age, and COPD severity. We compared short- and long-term mortality between COPD patients with and without PH. To ensure the reliability of our findings, we performed a sensitivity analysis by excluding patients who had not undergone echocardiography. Among 215,292 patients hospitalized primarily for COPD, we found an average COPD-related PH prevalence of 39.9 per 1000 individuals. The annual trend significant declined in prevalence among men but was comparable among women. Furthermore, a higher frequency of COPD-related hospitalization or emergency department visits correlated with an elevated COPD-related PH prevalence, irrespective of age. In comparison to COPD patients without PH, those with this condition exhibited notably higher one-year, three-year, and five-year mortality rates. Collectively, despite a declining trend in COPD-related PH prevalence among COPD patients, its development is closely linked to the severity of COPD. Given the significantly increased mortality rates in COPD patients with PH, early detection of this condition and the implementation of related interventions should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.